BACKGROUND
It has been suggested that apolipoprotein E (
APOE)
polymorphisms are associated with the risk of developing inflammatory bowel disease (IBD) and the early age of disease onset. However, there are no reports regarding the relationship with clinical characteristics and disease severity.
AIM
To summarise that APOE polymorphisms are associated with the risk of developing IBD and the early age of disease onset.
METHODS
In total, 406 patients aged 3-18 with IBD (192 had ulcerative colitis and 214 had Crohn’s disease) were genotyped using the TaqMan hydrolysis probe assay. Clinical expression was described at diagnosis and the worst flare by disease activity scales, albumin and C-reactive protein levels, localisation and behaviour (Paris classification). Systemic steroid intake with the total number of courses, immunosuppressive, biological, and surgical treatment with the time and age of the first intervention were determined. The total number of exacerbation-caused hospitalisations, the number of days spent in hospital due to exacerbation, the number of relapses, and severe relapses were also estimated.
RESULTS
Ulcerative colitis patients with the
APOEε4
allele had lower C-reactive protein values at diagnosis (
P
= 0.0435) and the worst flare (
P
= 0.0013) compared to patients with the
APOEε2
allele and genotype
APOEε3/ε3
. Crohn’s disease patients with the
APOEε2
allele scored lower on the Pediatric Crohn’s Disease Activity Index at diagnosis (
P
= 0.0204). IBD patients with
APOEε2
allele spent fewer days in the hospital due to relapse (
P
= 0.0440).
CONCLUSION
APOE
polymorphisms are associated with the risk of developing IBD and the clinical expression of IBD. However, the clinical relevance of the differences identified is rather modest.